Level 1myelomapositive2024 · 2024-04-12
Oncologic Drugs Advisory Committee, U.S. Food and Drug Administration. FDA ODAC meeting minutes.
ODAC voted Yes 12, No 0, Abstain 0 on: 'Does the evidence support the use of MRD as an accelerated approval endpoint in MM clinical trials?' Committee discussion supported use in both newly diagnosed and relapsed/refractory settings, with 9-month, 12-month, and MRD-negative CR at any time considered acceptable assessment timepoints. Minutes approved July 2, 2024.
IMF account of the vote
Level 1myelomapositive2026 · 2026-01-20
U.S. Food and Drug Administration (OCE, CDER, CBER, CDRH). FDA draft guidance; Docket FDA-2025-D-2616. Bone-marrow flow cytometry or sequencing; threshold of at least 1 in 10^5
Draft guidance, posted on the FDA site on January 20, 2026 (Federal Register notice January 21, 2026). Recommends MRD-negativity rate (in patients who have achieved CR or stringent CR), assessed in bone marrow by flow or sequencing, and CR rate as primary endpoints to support accelerated approval. MRD negativity should be assessed at a threshold of at least 1 in 10^5 residual tumor cells; alternate thresholds require justification. Verification of clinical benefit (typically PFS or OS) will generally be required, and confirmatory trial(s) should generally be underway prior to accelerated approval. Comments were due March 23, 2026.
PDFFederal Register notice
Level 1myelomapositive2026 · 2026-08-13
U.S. Food and Drug Administration. FDA Cancer Approvals. MRD-negative complete response at any time (EXCALIBER-RRMM) · n=420
Accelerated approval on August 13, 2026, for adults with multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, in combination with daratumumab and hyaluronidase-fihj and dexamethasone. In the first 420 randomized patients (IberDd n=207 vs DVd n=213), MRD-negative CR at any time was 41% (95% CI 34-48) vs 21% (95% CI 15-27), p<0.0001. Continued approval may depend on confirmatory verification of clinical benefit. The trial remains ongoing for PFS.
Prescribing information
Level 1myeloma/ALLpositive2018 · 2018-09-28
U.S. Food and Drug Administration. FDA press announcement (De Novo DEN170080). clonoSEQ NGS, bone marrow
On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).
De Novo decision summary
Consensusmyelomapositive2016
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, et al.. Lancet Oncol. PMID 27511158. Flow cytometry or sequencing MRD, with or without imaging
IMWG defined MRD-negativity response categories (with or without imaging-based absence of extramedullary disease) to allow uniform reporting, using bone-marrow flow or sequencing plus sensitive imaging, on top of conventional CR.
Level 2myelomapositive2017
Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al.. JAMA Oncol. PMID 27632282. Heterogeneous MRD methods across included studies · n=1,273 (PFS, 14 studies); 1,100 (OS, 12 studies)
Among 21 eligible studies, MRD negativity was associated with better PFS (HR 0.41, 95% CI 0.36-0.48, P<.001) and OS (HR 0.57, 95% CI 0.46-0.71, P<.001). In patients already in conventional CR, PFS HR was 0.44 (0.34-0.56) and OS HR 0.47 (0.33-0.67).
Full text
Level 3myelomapositive2017
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al.. Leukemia. PMID 28104919. EuroFlow NGF, bone marrow · n=110
EuroFlow 2-tube 8-color NGF with acquisition of ≥10^7 cells; LOD <2×10^-6 and LOQ <5×10^-6. In 110 BM samples from patients in VGPR or CR, MRD-positive rate was 47% by NGF vs 34% by conventional 8-color flow (P=0.003); 25% of conventional MRD-negative cases were NGF-positive. NGF MRD-negative vs MRD-positive CR patients had longer PFS (75% PFS not reached vs 7 months; P=0.02).
Full text
Level 2myelomapositive2020
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al.. Blood Adv. PMID 33284948. Heterogeneous (flow and sequencing) across 44 studies · n=8,098 (PFS, 44 studies); 4,297 (OS, 23 studies)
MRD negativity vs positivity improved PFS (HR 0.33, 95% CI 0.29-0.37, P<.001) and OS (HR 0.45, 95% CI 0.39-0.51, P<.001), including across newly diagnosed and relapsed/refractory disease, MRD thresholds, cytogenetic risk, and method of assessment.
Full text
Level 2myelomapositive2020
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al.. Blood. PMID 32325490. MRD (NGS, 10^-5) as a key secondary endpoint · n=207
Randomized phase 2 trial of D-RVd vs RVd in 207 transplant-eligible NDMM patients. Primary endpoint, sCR by the end of post-ASCT consolidation, was 42.4% vs 32.0% (OR 1.57, 95% CI 0.87-2.82; 1-sided P=0.068), meeting the prespecified 1-sided alpha of 0.10. With median follow-up 22.1 months, sCR improved to 62.6% vs 45.4% (P=0.0177) and MRD negativity (10^-5, ITT) was 51.0% vs 20.4% (P<.0001). 24-month PFS 95.8% vs 89.8%. MRD analysis of a randomized phase 2 trial (level 2), not MRD-guided therapy.
Full text
Level 2myelomamixed2022
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al.. J Clin Oncol. PMID 34898239. NGS MRD (clonoSEQ lineage), 10^-5 primary; 10^-6 also reported · n=123
Single-arm phase 2 MRD-adapted Dara-KRd with AHCT (n=123). Primary endpoint MRD <10^-5: 80% overall (78%, 82%, and 79% for 0, 1, and 2+ HRCAs); 66% reached MRD <10^-6; 71% had two consecutive MRD-negative assessments and entered treatment-free surveillance. Two-year PFS was 87% (91%, 97%, and 58% for 0, 1, and 2+ HRCAs). 12-month incidence of MRD resurgence or progression after cessation was 4%, 0%, and 27% by HRCA group. Not a randomized trial, so filed as level 2 despite being MRD-guided.
Level 2myelomamixed2023
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al.. Lancet Haematol. PMID 37776872. NGS MRD, 10^-5 (MRD-evaluable n=118 of 123) · n=123
Final analysis, median follow-up 42.2 months. Of 118 MRD-evaluable patients, 96 (81%, 95% CI 73-88) reached MRD <10^-5 and 84 (71%, 62-79) reached MRD-SURE and stopped therapy. 36-month PFS: 88% (no HRCA), 79% (1 HRCA), 50% (2+ HRCAs). Among 84 who stopped therapy, 24-month cumulative incidence of progression from cessation was 9%, 9%, and 47% by HRCA group. MRD-adapted cessation was feasible in 0-1 HRCA disease; patients with 2+ HRCAs had higher progression after stopping.
Full text
Level 2myelomapositive2022
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al.. Lancet Haematol. PMID 36328040. Flow-cytometry MRD after induction (primary endpoint of part 1) · n=660
Phase 3, 660 transplant-eligible NDMM patients (331 Isa-VRd, 329 VRd) in Germany. MRD negativity after induction (ITT) was reached in 166 (50%) vs 117 (36%) (OR 1.82, 95% CI 1.33-2.48; p=0.00017). Grade 3-4 neutropenia 23% vs 7%. MRD analysis of an RCT (level 2), not MRD-guided therapy. NCT03617731.
Level 2myelomapositive2025
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al.. J Clin Oncol. PMID 39652594. MRD after Isa-VRd vs VRd induction · n=662
Final part 1 analysis of GMMG-HD7 (331 Isa-RVd, 329 RVd). MRD-negativity rates continued to deepen after transplant (66% Isa-RVd vs 48% RVd). Isa-RVd induction significantly prolonged PFS vs RVd regardless of maintenance (HR 0.70, 95% CI 0.52-0.95, P=0.0184). Level 2 (MRD and PFS analysis of a randomized trial).
Full text
Level 2myelomapositive2024
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al.. N Engl J Med. PMID 38084760. MRD negativity as a key secondary endpoint (threshold as prespecified in the protocol; reported as MRD-negative status) · n=709
Phase 3 trial, 709 transplant-eligible NDMM patients randomized to D-VRd (with D-R maintenance) vs VRd (with R maintenance). At median follow-up 47.5 months, 48-month PFS was 84.3% vs 67.7% (HR 0.42, 95% CI 0.30-0.59, P<0.001). CR or better 87.9% vs 70.1% (P<0.001); MRD-negative status 75.2% vs 47.5% (P<0.001). MRD analysis of an RCT (level 2), not MRD-guided therapy.
Level 2myelomapositive2024
Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al.. Blood. PMID 38768337. MRD negativity at 12±3 months (trial-level and individual-level association with PFS) · n=4907
FDA-aligned meta-analysis of 8 newly diagnosed MM randomized trials (n=4,907). Trial-level association between 12-month MRD negativity and PFS: R²_WLSiv 0.67 (95% CI 0.43-0.91) and R²_copula 0.84 (0.64 to >0.99). Individual-level global OR for 12-month MRD negativity and PFS was 4.02 (95% CI 2.57-5.46) in NDMM and 7.67 (4.24-11.10) in 4 relapsed/refractory studies. Supported the case that a treatment effect on MRD is reasonably likely to predict a treatment effect on PFS. One of the two meta-analyses presented at the April 2024 ODAC.
Full text
Level 2myelomapositive2025
Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, et al.. J Clin Oncol. PMID 39938021. MRD-negative CR at 10^-5, at 9 or 12 months · n=4773
Individual-patient meta-analysis from 20 randomized trials; 11 studies (4,773 patients) evaluated 9- or 12-month MRD-CR at a 10^-5 threshold as an intermediate endpoint for PFS/OS in ND transplant-eligible, ND transplant-ineligible, and RRMM. Patient-level global ORs for MRD-CR and PFS ranged from 3.06 to 16.24 (all 95% CIs excluded 1.0). Trial-level R² 0.61-0.70 overall and 0.67-0.78 in newly diagnosed disease. Supported use of 9- or 12-month MRD-CR at 10^-5 as an intermediate endpoint for accelerated approval. This is the i2TEAMM pooled analysis presented at ODAC.
Level 2myelomapositive2025
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, et al.. Blood. PMID 39841461. NGS MRD at 10^-5 and 10^-6 after Isa-KRd induction · n=791
Induction analysis of the MRD-adapted MIDAS trial: 791 patients received six 28-day cycles of Isa-KRd. 96% completed induction; best ORR 95%; 91% achieved VGPR or better. In the ITT population, MRD-negativity rates after induction were 63% at 10^-5 and 47% at 10^-6.
Full text
Level 1myelomamixed2025
Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al.. N Engl J Med. PMID 40459097. NGS MRD, 10^-5 to assign consolidation; primary endpoint 10^-6 MRD negativity before maintenance · n=485 MRD-negative at 10^-5 after induction; 233 MRD-positive at 10^-5
Phase 3 randomized MRD-guided consolidation after Isa-KRd induction. Among 485 patients MRD-negative at 10^-5 after induction, premaintenance MRD negativity at 10^-6 was 86% with ASCT + 2 cycles Isa-KRd vs 84% with 6 cycles Isa-KRd without ASCT (adjusted RR 1.02, 95% CI 0.95-1.10, P=0.64). Among 233 patients MRD-positive at 10^-5, premaintenance 10^-6 negativity was 32% with tandem ASCT vs 40% with single ASCT + Isa-KRd (adjusted RR 0.82, 95% CI 0.58-1.15, P=0.31). Median follow-up about 16-17 months. Neither intensification strategy significantly improved the 10^-6 MRD endpoint. Level 1 (randomized MRD-guided trial).
Full text
Level 3myelomamixed2024
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Blood Cancer J. PMID 39375362. Multimodal: PET, BM flow (LoD 10^-5), BM clonoSEQ (LoD 10^-6), plus CD138-enriched clonoSEQ toward 10^-7 · n=47
Pragmatic trial: 47 patients with prior MRD <10^-5, ≥1 year of maintenance, and prospectively confirmed undetectable disease by PET, BM flow (10^-5), and BM clonoSEQ (10^-6) discontinued maintenance (median prior maintenance 36 months). Median post-discontinuation follow-up 30 months. Baseline MRD ≥10^-7 in 9/47 (19%). Estimated 3-year cumulative incidence of disease resurgence was 20% if baseline MRD <10^-7 vs 75% if ≥10^-7 (HR 7.8, 95% CI 2.2-27.6, P=0.001); 3-year PFS 92% vs 49% (HR 10.1, 95% CI 1.6-62.3). Small single-arm study (level 3).
Full textASCO abstract 106ClinicalTrials.gov NCT04108624
Level 2myelomapositive2025
Corre J, Vincent L, Moreau P, Hebraud B, Hulin C, Béné MC, et al.. Blood. PMID 40127397. MRD at 10^-5 and 10^-6 at prespecified time points
Long-term MRD and PFS after median follow-up 80.1 months. D-VTd improved MRD-negativity (10^-5) after induction (34.6% vs 23.1%) and consolidation (63.7% vs 43.7%) vs VTd. Daratumumab maintenance (fixed duration ≤2 years vs observation; not MRD-guided) further improved MRD-negativity (D-VTd/dara vs D-VTd/observation: 10^-5 77.3% vs 70.7%, 10^-6 60.7% vs 52.0%; VTd/dara vs VTd/observation: 10^-5 70.9% vs 51.2%, 10^-6 48.4% vs 30.7%) and provided PFS benefit regardless of post-consolidation MRD status. Correction: this is not an MRD-guided maintenance trial.
Full text
Level 2myelomapositive2025
Usmani SZ, Facon T, Hungria V, Bahlis NJ, et al.. Nat Med. PMID 39910273. MRD negativity (and sustained MRD negativity) as a key endpoint · n=395
Phase 3 D-VRd vs VRd in transplant-ineligible or transplant-deferred NDMM. At median follow-up 58.7 months, MRD-negativity rate 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<0.0001); ≥CR 81.2% vs 61.6% (P<0.0001); sustained MRD negativity ≥12 months 48.7% vs 26.3% (P<0.0001). Risk of progression or death was 43% lower with D-VRd (HR 0.57, 95% CI 0.41-0.79, P=0.0005). Level 2. A dedicated MRD analysis is Zweegman et al., Blood Adv 2026 (PMID 42234958).
Full text
Level 3myelomapositive2024
Fan H, Wang B, Shi L, Pan N, et al.. Clin Cancer Res. PMID 38170583. EasyM clonotypic serum mass spectrometry
Method and clinical-monitoring paper for EasyM, a peripheral-blood clonotypic mass-spectrometry assay tracking serum M-protein for MRD in myeloma.
Full text
Level 3myelomapositive2025
Zhao J, Khong T, Gorniak M, Khaled A, et al.. Haematologica. PMID 39506908. EasyM (serum MS) vs EuroFlow NGF (bone marrow)
Head-to-head comparison of the blood-based EasyM clonotypic mass-spectrometry assay with EuroFlow bone-marrow MRD in myeloma (Haematologica 2025). The PubMed record did not include a structured abstract with numeric concordance rates at retrieval, so rates are not restated here; the paper and DOI were verified.
Full text
Level 1myelomapending2019
SWOG / NCI NCTN. ClinicalTrials.gov. MRD-adapted maintenance duration
Ongoing randomized MRD-adapted maintenance trial. No primary efficacy results paper was identified as of this review. Included as a level-1-design trial (MRD-integral randomization) without outcome data.
Level 2myelomapositive2026
Zweegman S, Facon T, Hungria V, Bahlis NJ, et al.. Blood Adv. PMID 42234958. MRD at 10^-5 and 10^-6, including sustained MRD negativity · n=395
395 patients (D-VRd 197, VRd 198), median follow-up 58.7 months. Overall MRD-negativity 10^-5: 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<.0001); 10^-6: 46.2% vs 27.3% (OR 2.24, 95% CI 1.48-3.40, P=0.0001). Sustained MRD negativity ≥12 months 10^-5: 49.2% vs 27.3%; 10^-6: 34.0% vs 16.2% (each P<.0001), with similar benefits at ≥24 and ≥36 months. Among patients who achieved MRD negativity, PFS trended in favor of D-VRd (10^-5 HR 0.61, 95% CI 0.35-1.06, P=0.0755).
Full text